What Actually Drives Patient Engagement in Clinical Trials?

When it comes to patient engagement in clinical trials, we often turn to recruitment and attrition metrics to measure success or failure. We track enrollment rates, retention rates, missed visits, protocol deviations, and patient withdrawals. We analyze recruitment challenges and investigate the reasons patients leave studies early.¹ While these metrics are important, they only tell us what happened, not why it happened.

The industry is not asking the simple question: what actually keeps patients engaged in the first place?

Firstly, it needs to be understood that patients rarely make participation decisions in isolation. Their ability to engage in research is influenced by where they live, the support available to them, the practical realities of daily life, and the trust they have in the people delivering their care.²

The trials most likely to sustain engagement are often those that recognize this reality early and design around it.³

Sponsors need to understand that engagement is not something that begins when a patient signs an informed consent form. It needs to be baked into the trial from very start: during protocol design, site selection, and operational planning. Long before the first patient enrolls, decisions are being made that will ultimately determine how easy, or difficult, it will be for patients and their families to participate.

As clinical research continues to expand beyond traditional academic centers, it has become increasingly clear that sustainable patient engagement is built through accessibility, trust, and support. Together, these factors influence whether participation becomes realistic, sustainable, and ultimately successful for both patients and study teams.^2,3

Accessibility creates the foundation for engagement

It is critical to understand that access to clinical trials does not equate to immediate engagement. Rather, it is the foundation on which sustainable enrollment and engagement can be built. Patients cannot participate if access to research is limited or unsustainable.⁴

Distance remains one of the most persistent challenges facing clinical trial participation. Travel requirements often extend beyond simply getting from one location to another. Patients may need to take time away from work, arrange transportation, find childcare, coordinate eldercare, or manage physical limitations associated with their condition.¹ For patients already managing chronic illnesses or complex conditions, these requirements can quickly become overwhelming.

This is particularly evident among rural populations, individuals with limited mobility, patients living with rare diseases, and historically underserved communities.⁵ These groups are often willing to participate but face practical barriers that make sustained engagement difficult.

Community-based clinical trial (CBCT) models can significantly change the participation experience. However, accessibility should not be confused with decentralization.

Over the last several years, decentralized clinical trial (DCT) elements have become increasingly popular, particularly in-home visits and remote assessments. These approaches can play an important role in reducing participation burden and creating more flexible participation pathways. But not every clinical trial can be conducted entirely outside of a clinical setting.

Many protocols require specialized equipment, investigational product handling, laboratory infrastructure, or clinical oversight that cannot always be replicated in a patient's home. While in-home visits and telehealth can reduce burden, they cannot always replace every site visit.

Instead of asking patients to travel to research, research can be brought closer to patients through mobile units that are created to be dedicated clinical environments. These are permanently placed directly within communities, reducing geographic barriers while offering many of the same capabilities traditionally associated with brick-and-mortar study sites.

However, accessibility is only the first step. Removing barriers may make enrollment possible, but it does not automatically make participation sustainable.

Patients do not participate alone

Enrollment and engagement are not the same thing. Even when participation becomes accessible, success often depends on factors that extend beyond the patient themselves.

When we consider patient engagement, there can be a tendency to focus entirely on the individual patient. The reality is that many clinical trials involve an entire support network.

Family members and caregivers often play a central role throughout the study journey. They help coordinate appointments, provide transportation, manage schedules, offer emotional support, and assist with treatment adherence. In some therapeutic areas, caregivers become essential partners in participation.^6,7

This is particularly true in indications involving neurological conditions, rare diseases, pediatric populations, and chronic illnesses that require long-term management. And yet caregiver burden often receives less attention despite its significant role in ongoing engagement.⁷

For a working parent, clinical trial participation may require coordinating school schedules and childcare. While an older adult may depend on the availability of a family member willing to provide transportation in order to participate. With individuals managing chronic conditions, caregivers often become responsible for helping maintain study requirements while continuing to support everyday life.

By bringing research into patient’s communities, travel requirements are reduced, scheduling flexibility can improve, and disruption to daily routines becomes more manageable. Families spend less time coordinating participation logistics and more time focusing on their health and wellbeing.

This shift does more than improve convenience, it helps make ongoing participation sustainable. Successfully engaging patients often means supporting the people who support them.

Trust turns participation into partnership

Accessibility may create opportunities for participation, but trust is what transforms opportunity into meaningful engagement.²

Trust is fundamental to every healthcare interaction, and clinical research is no exception. Patients want to know that their concerns will be heard. They want to understand why procedures are necessary. They want confidence that the commitment they are making is worthwhile. And, most importantly, they want to feel like partners rather than subjects.²

Trust is rarely created through a single interaction. It develops through consistency, communication, familiarity, and the confidence that concerns will be heard and acted upon. Study teams embedded within and reflective of the communities they serve are often better positioned to navigate cultural considerations, communicate in meaningful ways, and build stronger patient relationships throughout the trial journey.⁸

Additionally, patients are often more comfortable discussing concerns, asking questions, and sharing experiences when interacting with healthcare professionals they perceive as familiar, approachable, and invested in their wellbeing.

The value of community-based models extends well beyond accessibility; it enables participation to transform from a transactional activity into a collaborative partnership. However, trust alone is not always enough to sustain participation throughout an entire clinical trial.

Support sustains participation over time

Enrollment is an event, but engagement is an ongoing process. Even highly motivated patients face challenges during long clinical trials. While accessibility may support enrollment and trust may strengthen participation, support is often what determines whether participation remains sustainable over time.^1,9

Clinical trial participation often involves ongoing procedures, treatment schedules, study assessments, lifestyle adjustments, and regular interactions with healthcare teams. Over weeks, months, or even years, these requirements can become difficult to manage.

Furthermore, the longer a trial runs, the more likely it becomes that patients will experience changes in their health, employment situation, caregiving responsibilities, financial circumstances, or broader life commitments. Without support, these challenges can become barriers, but with support, they become manageable.

In many ways, support becomes a natural extension of trust. When patients feel comfortable raising concerns, study teams are better able to identify challenges early and provide practical support before those challenges become barriers to continued participation. And when study teams understand the practical realities patients face, they are better positioned to provide meaningful support when it is needed.

Support does not eliminate barriers entirely, but it helps prevent those barriers from becoming reasons to disengage.

Why community-based models bring access, trust, and support together

Patient engagement is often discussed as though it is something patients either have or do not have. However, participation in clinical research is rarely that simple.

The decision to enroll, remain engaged, and ultimately complete a clinical trial is influenced by a wide range of factors that exist beyond the protocol itself. Patients must balance participation alongside work, family responsibilities, caregiving commitments, existing healthcare needs, and the realities of everyday life.

When participation becomes difficult to access, trust can be difficult to establish. When trust is absent, patients may be less willing to share concerns or seek support. And when challenges arise without the right support structures in place, even the most motivated patients can begin to question whether continued participation is sustainable.

This is why patient engagement cannot be viewed as a single intervention or outcome measure. Rather, it is the result of how well a trial fits into the lives of the people it is intended to serve.

Community-based models have an important role to play in this shift. Not simply because they bring research closer to patients, but because they bring accessibility, trust, and support together within a single patient experience.

Ultimately, the industry needs to move beyond asking how to make patients engage with clinical trials and instead ask how clinical trials can better support the patients they hope to engage.

Because engagement does not begin at enrollment. It must be built into the patient experience from the very beginning.

References:

1. Chaudhari, Nayan et al. “Recruitment and retention of the participants in clinical trials: Challenges and solutions.” Perspectives in clinical research vol. 11,2 (2020): 64-69. doi:10.4103/picr.PICR_206_19
2. Blom, Johanna M C et al. “Building trust in clinical research: a systems approach to ethical engagement and sustainable outcomes.” Frontiers in pharmacology vol. 16 1570899. 16 Jul. 2025, doi:10.3389/fphar.2025.1570899
3. Anastasi, Joyce K et al. “Recruitment and retention of clinical trial participants: understanding motivations of patients with chronic pain and other populations.” Frontiers in pain research (Lausanne, Switzerland) vol. 4 1330937. 28 Mar. 2024, doi:10.3389/fpain.2023.1330937
4. Gobat N, et al. “Better engagement, better evidence: working in partnership with patients, the public, and communities in clinical trials with involvement and good participatory practice.” The Lancet Global Health, 13, e716-e731. April 2025
5. Chalela, Patricia et al. “Promoting Factors and Barriers to Participation in Early Phase Clinical Trials: Patients Perspectives.” Journal of community medicine & health education vol. 4,281 (2014): 1000281. doi:10.4172/2161-0711.1000281
6. Blackstone, Eric C et al. “Stakeholder perspectives on the role of caregivers in cancer clinical trial decision-making: results of a qualitative study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer vol. 33,6 464. 10 May. 2025, doi:10.1007/s00520-025-09505-7
7. Miranda A, et al.” Where are caregivers in the clinical trial? Evaluation of caregiver responsibilities in Alzheimer's disease and related dementias clinical trials.” Alzheimers Dement. 2023 Nov;19(11):5316-5322. doi: 10.1002/alz.13418. Epub 2023 Aug 18. PMID: 37594028.
8. Bodicoat, Danielle H et al. “Promoting inclusion in clinical trials-a rapid review of the literature and recommendations for action.” Trials vol. 22,1 880. 4 Dec. 2021, doi:10.1186/s13063-021-05849-7
9. Huddar, Siddharth et al. “Trust, altruism, and ease of participation in a fully remote, decentralized COVID-19 clinical trial.” Social Sciences & Humanities Open, Volume 13, 2026, 103009, ISSN 2590-2911, https://doi.org/10.1016/j.ssaho.2026.103009. Last Accessed August 2026.